1. A. The "medical use of psilocybin program" is created in the department. In developing the program, the department shall establish:

   1. (1) appropriate qualifying conditions for qualified patients;
   2. (2) necessary initial and ongoing training for producers and clinicians;
   3. (3) treatment protocols, including patient selection criteria, medical service standards, dosage standards and approved settings for administration of psilocybin to patients;
   4. (4) safety protocols for producing psilocybin from mushrooms, transporting, storing and handling psilocybin and treating patients;
   5. (5) other best practices for producers and clinicians;
   6. (6) requirements for data collection to evaluate the program and the use of best practices by producers and clinicians; and
   7. (7) other requirements, restrictions and limitations promulgated by the department to ensure an efficacious program.
2. B. The department shall monitor producers and clinicians to ensure compliance with the Medical Psilocybin Act and rules promulgated in accordance with that act.
3. C. The department shall collaborate with the board, state higher education institutions and health care providers to collect and analyze data to develop best practices, including best settings for administration of psilocybin, and, by December 31, 2027, implement the program. When developing the program, the department shall engage in tribal consultation as provided in the State-Tribal Collaboration Act [Chapter 11, Article 18 NMSA 1978].

History: Laws 2025, ch. 73, § 7.

ANNOTATIONS

Effective dates. — Laws 2025, ch. 73 contained no effective date provision, but, pursuant to N.M. Const., art. IV, § 23, was effective June 20, 2025, 90 days after adjournment of the legislature.